Linked Life Data

2759923

Source:http://linkedlifedata.com/resource/pubmed/id/2759923

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1989-9-15
pubmed:abstractText
An open multicentre study of the efficacy and side effects of roxithromycin, a new macrolide antibiotic, in the treatment of community acquired pneumonia was undertaken. The diagnosis was verified by transtracheal aspiration. Fifty-three patients were studied. In the 49 patients evaluable the clinical efficacy rate was 92% (95% confidence limits 84-100%). Only by measurement of the fall in serum C-reactive protein was it possible to detect a difference in response between pneumonia due to Streptococcus pneumoniae and Haemophilus influenzae. The drug was well tolerated clinically and laboratory abnormalities included transient eosinophilia and elevated liver enzymes in two patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0305-7453
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
737-41
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Roxithromycin in the treatment of pneumonia.
pubmed:affiliation
Department of Infectious Diseases, Marselisborg Hospital, Aarhus C, Denmark.
pubmed:publicationType
Journal Article